designed so that advances are made efficiently. The field has been dominated by smaller Phase II studies since they provide the initial screening of drug efficacy. These studies are prone
oncology, several have reached Phase III trials and many more are in Phase I and II. In addition to this, multiple novel drugs, including more targeted agents, are emerging from
inducing mitotic arrest and apoptosis, and aggregates soluble tubulin in a nonproductive form. In Phase II studies, this drug gave a partial response and stable disease. The EMBRACE study showed
second option would have Phase I trials for pregnant women embedded into late Phase II or Phase III trials, with enhanced monitoring for pregnant women, similar to that done
with limited treatment options. Telaprevir, a NS3/4A HCV protease inhibitor, was shown in Phase II studies to be efficacious and safe in treatment-naive and treatment-experienced genotype
safety and tolerability of this agent has been largely demonstrated. Preliminary results of Phase II trials have shown edoxaban to be potentially advantageous to traditional anticoagulants in terms of bleeding
used as surrogate end points to reliably predict long-term clinical outcomes in Phase II and III trials, designing trials to evaluate new drugs for drug-resistant TB, better approaches
patients with metastatic castration-resistant prostate cancer and showed promising results in Phase I and II studies with prostate specific antigen and radiological responses. In a randomized Phase III trial
rearranged NSCLC patients with a response rate of 51–61% in a Phase I and II study with an estimated median progression-free survival of approximately 10 months
nitrogen or photodynamic therapy. On 5 March 2012 we conducted a Medline search for Phase II and III trials of novel medical treatments that have been reported within the last
results, as well as indications of efficacy as tumor VDAs, have been obtained in Phase II clinical trials. However, Phase III trials have not yet demonstrated an increase in patient
nodules are frequently encircled by fibroblast-like cells. The expression of FasL, a type II transmembrane protein of the tumor necrosis factor family and widely expressed in various cancers, correlates ... cells by…
therapeutic interventions. Developments after Molecular Biology revolution (1953) are discussed as successions of three phases. The first, PH1, labeled âÂ?Â?Clonal OutgrowthâÂ? (from 1960s to mid 1980s) was…
this disease and mostly non-operability due to advanced disease. We report on a phase II study on isolated thoracic perfusion (ITP) with subsequent chemofiltration (ITP-F) as arnlocoregional therapeutic
plasma half-life compared with tissue plasminogen activator in experimental stroke models. The Phase II trials DIAS and DEDAS indicated that intravenous desmoteplase administered within 3–9 h after stroke
outcome of salvage therapy. New molecules and antibodies are being investigated in Phase I/II studies in patients who have relapsed or exhibit primary refractoriness and in those not eligible
FRDA failed to prove disease modifying properties of candidate substances until to date. Phase II studies attributed idebenone, a synthetic short chain quinine analogue of co-enzyme Q10, some clinical ... substances are…
models of ALK-rearranged lung cancer, and has demonstrated high response rates in Phase I/II clinical trials in this sub-population. This review summarizes ALK biology, recent developments
advance promising agents rapidly into clinical development. We review the adaptations to traditional Phase I and II clinical trial design that are hoped to address some of the current challenges
viral oncogene homolog 1, and also active against a wide range of mutant clones. Phase II trials of nilotinib showed high activity in imatinib-resistant or -intolerant chronic myeloid leukemia ... frontline treatment…
extraction method was used for the preconcentration and extraction of cadmium (II) and zinc (II) ions in different environmental samples. The zinc and cadmium ions formed hydrophobic complexes with phenanthraquinone…
Hepatic mRNA and protein expression of Car target genes (phase I, II and transporters) were quantified on gestation day 17. Pregnancy-related changes, such as induction of Cyp2b10, Ugt1a1
chelating ligand, which was treated with the ions Rh(III), Pd(II), Cd(II) and Pt(IV) in alcoholic medium in order to prepare series of new metal complexes. These ... stable in molar ratio 1:1. A theoretical treatment of…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.